

Enzymatic Determination of the Anomeric Structures of Two Blood-Group B Active Glycosphingolipids Recombined with Apolipoproteins

Peter Hanfland

Institut für Experimentelle Hämatologie und Bluttransfusionswesen der Universität Bonn

Gerd Assmann

Abteilung für Klinische Chemie und Zentrallabor der Universitätskliniken, Köln

and

Heinz Egge

Institut für Physiologische Chemie der Universität Bonn

Z. Naturforsch. **33 c**, 73–78 (1978) ; received July 14/October 3, 1977

Blood-Group Glycolipids, Anomeric Structure, Enzymatic Degradation, Apolipoproteins

Anomeric configuration of oligosaccharides usually is established by specific glycosidases. For this purpose detergents achieving water solubility of primarily insoluble glycosphingolipids as substrates have been replaced by delipidated human serum high density lipoproteins. The new method, tested by several well characterized glycosphingolipids and glycosidases, finally was applied to the evaluation of anomeric structures of two blood-group B active glycosphingolipids [ceramide hexasaccharide (B-I) and ceramide octasaccharide (B-II)] from human erythrocyte membranes. In both B-I and B-II, α -glycosidic linkage was demonstrated for the terminal galactose and fucose residues. β -glycosidic linkage has been evaluated for backbone saccharides. Together with the results previously obtained by composition analysis, linkage analysis and sequence analysis the following complete structure can be established:

B-I: Gal α 1 \rightarrow 3Gal(2 \leftarrow 1 α Fuc) β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow 1Cer;

B-II: Gal α 1 \rightarrow 3Gal(2 \leftarrow 1 α Fuc) β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow 1Cer.

Introduction

The biological importance of glycosphingolipids concerning blood-group activities, cellular recognition, regulation of cell growth and malignant transformation^{1,2} has promoted the development of microscale characterization methods: combined gas-chromatography-mass spectrometry of partially methylated alditol acetates^{3–5}, direct inlet mass spectrometry of permethylated glycolipids^{6–8} and enzymatic degradation by specific glycosidases^{9,10}

allow to evaluate sugar linkage and sequence as well as anomeric configuration, respectively. Because of the water-insolubility of glycosphingolipids, detergents (taurocholate, cholate, Triton X-100) have been previously applied in enzymatic analysis^{11–20}. In the present investigation, these detergents have been replaced by the use of delipidated human serum high density lipoproteins (apoHDL). Glycosphingolipid-apoprotein complexes proved to be suitable substrates for several glycosidases. Glycosphingolipids used at first for these purposes

Requests for reprints should be sent to Dr. Peter Hanfland-Institut für Experimentelle Hämatologie und Bluttransfusionswesen der Universität Bonn, Annaberger Weg, D-5300 Bonn 1.

Abbreviations (in accordance with the IUPAC-IUB recommendations, Hoppe-Seyler's Z. Physiol. Chem. **358**, 617–631 [1977]): glycosphingolipids from human erythrocyte membranes: LcOse₂Cer_{Hu}, ceramide disaccharide; GbOse₃Cer_{Hu}, ceramide trisaccharide; nLcOse₄Cer_{Hu}, lacto-N-neotetraosylceramide; GbOse₄Cer_{Hu}, globoside; B-I, blood-group B active ceramide hexasaccharide; B-II, blood-group B active ceramide octasaccharide; H_b-I, ceramide pentasaccharide from B-I after α -galactosidase

treatment; H_b-II, ceramide heptasaccharide from B-II after α -galactosidase treatment; Tetra_b-I, ceramide tetrasaccharide from H_b-I and Hexa_b-II ceramide, hexasaccharide from H_b-II after partial hydrolysis with 0.1 N trichloroacetic acid or α -fucosidase treatment; C5S_b, ceramide pentasaccharide from B-I after α -fucosidase treatment; C7S_b, ceramide heptasaccharide from B-II after α -fucosidase treatment; glycosphingolipids from rabbit erythrocyte membranes: GbOse₃Cer_{Rab}, ceramide trisaccharide; C5S_{Rab}, ceramide pentasaccharide; nLcOse₄Cer_{Rab}, lacto-N-neotetraosylceramide from C5S_{Rab} after α -galactosidase treatment; HDL, high density lipoprotein; apo HDL, delipidated high density lipoprotein.



Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namensnennung-Keine Bearbeitung 3.0 Deutschland Lizenz.

Zum 01.01.2015 ist eine Anpassung der Lizenzbedingungen (Entfall der Creative Commons Lizenzbedingung „Keine Bearbeitung“) beabsichtigt, um eine Nachnutzung auch im Rahmen zukünftiger wissenschaftlicher Nutzungsformen zu ermöglichen.

This work has been digitalized and published in 2013 by Verlag Zeitschrift für Naturforschung in cooperation with the Max Planck Society for the Advancement of Science under a Creative Commons Attribution-NoDerivs 3.0 Germany License.

On 01.01.2015 it is planned to change the License Conditions (the removal of the Creative Commons License condition "no derivative works"). This is to allow reuse in the area of future scientific usage.

all have been extensively characterized including their anomeric structures. Additionally, the new assay was applied to the evaluation of the anomeric configurations of two blood-group B active glycosphingolipids from human erythrocyte membranes. They represent a ceramide hexasaccharide (B-I), which already has been characterized by Koscielak *et al.*²¹ and a ceramide octasaccharide (B-II). Composition, sugar linkage and sequence of both glycosphingolipids previously have been studied in our laboratories^{22–24}. In consequence, the complete structure of B-II now can be presented for the first time.

Materials and Methods

Isolation of glycosphingolipids

LcOse₂Cer_{hu}, GbOse₃Cer_{hu}, nLcOse₄Cer_{hu}, GbOse₄Cer_{hu}, B-I and B-II were isolated from human erythrocyte membranes²². H_b-I and H_b-II were prepared from B-I and B-II by α -galactosidase treatment²³. Removal of the terminal fucosyl residue by 0.1 N trichloroacetic acid at 100 °C for 2 hours²⁵ from H_b-I and H_b-II yielded Tetra_b-I and Hexa_b-II, respectively²³. GbOse₃Cer_{rab} and C5S_{rab} were isolated according to Eto *et al.*²⁶. nLcOse₄Cer_{rab} was obtained from ceramide pentasaccharide by α -galactosidase treatment (see below). Glucocerebroside was obtained after partial hydrolysis of a crude human ganglioside fraction (slightly contaminated by sulfatides) with 0.05 N HCl for 45 min at 100 °C. This cerebroside fraction was further purified by silicic acid column chromatography.

Enzyme sources

α -Galactosidase (E.C. 3.2.1.22) from coffee beans (10 U/mg), N-acetyl- β -D-hexosaminidase (E.C. 3.2.1.30) from bovine kidney (0.6 U/mg with *p*-nitrophenyl-N-acetyl- β -D-galactosaminide as substrate) and α -L-fucosidase (E.C. 3.2.1.51) from bovine kidney (2 U/mg) were purchased from Boehringer, Mannheim. β -Galactosidase from jack bean (0.25 U/mg) and N-acetyl- β -D-hexosaminidase (0.5 U/mg) from jack bean (isolated according to Li and Li⁹) were a generous gift from Prof. Lagrou and Dr. van Dessel, Laboratory of Biochemistry, University of Antwerpen. β -Galactosidase from *Charonia lampas* (1.1 U/mg) was purchased from Miles, Frankfurt. α -L-fucosidase from *Charonia lampas* (4.5 U/mg) was provided by Dr. P. Okuyama of Seikagaku Chemical Co., Tokyo.

Preparation of apo HDL

HDL used in these studies was obtained from the plasma of three male volunteers. The lipoproteins

were isolated by preparative ultracentrifugal flotation between KBr densities 1.063 and 1.210 g/ml, and delipidated with chloroform-methanol, 2 : 1²⁷. Apo HDL was solubilized in 0.05 M NH₄HCO₃ buffer, pH 8.8 (5 mg/ml).

Reassembly procedure

Individual glycosphingolipids (250 μ g/ml) were sonicated in water and yielded clear dispersions on sonication for 5–10 min. Apo HDL was added to the sonicated glycosphingolipids (2 : 1 w/w) and then subjected, in an ice bath and under nitrogen, to short sonication (3 \times 10 sec) with a microtip probe of a Branson sonifier at a probe setting of 5. The sonicated protein-lipid solutions were dialysed against 1.000 volumes of incubation buffers (0.05 M) at 4 °C and used within 4 hours for enzymatic degradation.

Enzymatic degradation

After dialysis of glycosphingolipid-apoprotein complexes enzyme protein was added and the resulting solutions were sterilized by millipore ultrafiltration (0.40 μ m) at 4 °C. Incubation was performed at 37 °C for 18 or 36 hours in sterile glass tubes containing a magnetic stirring bar with screw caps teflon lined on the inside (see also Table I). Incubations were stopped by freezing. After lyophilization, glycosphingolipid reaction products were extracted with chloroform-methanol 2 : 1 v/v, 1 : 2 v/v and/or chloroform-methanol-water 1 : 1 : 0.1. Glycosphingolipids were analyzed by chromatography with authentic compounds. For glucocerebroside identification, borate plates were used with chloroform-methanol-water-15 M NH₄OH (280 : 70 : 6 : 1) as solvent system²⁸. The spots were visualized by spraying with 5% sulfuric acid in water and heating at 125 °C or with anthrone reagent²⁹. Substrate-product ratios were estimated by the degree of disappearance of the original glycosphingolipid and by the appearance of the new glycolipid as a degradation product.

Results and Discussion

The conversion rates of glycosphingolipids after incubation in the presence of apolipoproteins or sodium taurocholate are listed in Table I. In most experiments, degradation of glycosphingolipids was observed, when apolipoprotein-glycolipid mixtures were employed as substrates for individual enzymes. Fig. 1 demonstrates the degradation of nLcOse₄Cer_{rab} to ceramide disaccharide as major and ceramide trisaccharide as minor reaction products in the

Table I. Enzyme-glycolipid incubation mixtures, reaction products and incubation conditions. See also "Materials and Methods". α -gal'ase c.b.: α -galactosidase from coffee bean, β -gal'ase j.b.: β -galactosidase from jack bean, β -h'ase j.b.: β -N-acetyl-hexosaminidase from jack bean, β -gal'ase c.l.: β -galactosidase from *Charonia lampas*, β -h'ase b.k.: β -N-acetyl-hexosaminidase from bovine kidney, α -fuc'ase b.k.: α -fucosidase from bovine kidney, α -fuc'ase c.l.: α -fucosidase from *Charonia lampas*.

No.	Substrate [100 μ g]	Enzyme	Amount of enzyme [units]	Product	Con- version rate [%]	Buffer	pH	Incuba- tion time [hr]
1	GbOse ₃ Cer _{hu}	α -gal'ase c.b.	2	LcOse ₂ Cer	50	Na phosphate	6.5	18
2	GbOse ₃ Cer _{rab}	α -gal'ase c.b.	2	LcOse ₂ Cer	50	Na phosphate	6.5	18
3	nLcOse ₄ Cer _{hu}	β -gal'ase j.b.	0.1	LcOse ₃ Cer	80	Na citrate	4.5	18
4	nLcOse ₄ Cer _{hu}	β -gal'ase c.l.	0.25	LcOse ₃ Cer	80	Na citrate	4.0	18
5	nLcOse ₄ Cer _{hu}	β -gal'ase + β -h'ase j.b.	0.4 + 0.4	LcOse ₂ Cer (Cerebroside)	80 (10)	Na citrate	4.5	36
6	nLcOse ₄ Cer _{hu}	β -gal'ase j.b.	0.1	LcOse ₃ Cer	80	Na citrate	4.5	18
7	nLcOse ₄ Cer _{hu}	β -gal'ase c.l.	0.25	LcOse ₃ Cer	80	Na citrate	4.0	18
8	nLcOse ₄ Cer _{rab}	β -gal'ase + β -h'ase j.b.	0.1 + 0.1	LcOse ₂ Cer	80	Na citrate	4.5	18
9	GbOse ₄ Cer _{hu}	β -h'ase b.k.	1.5	GbOse ₃ Cer	50	Na citrate	4.5	18
10	C5S _{rab}	α -gal'ase c.b.	1	nLcOse ₄ Cer	100	Na phosphate	6.5	18
11	B-I	α -gal'ase c.b.	1	H _b -I	100	Na phosphate	6.5	18
12	B-II	α -gal'ase c.b.	1	H _b -II	100	Na phosphate	6.5	18
13	B-I	α -fuc'ase b.k.	2	C5S _b	traces	Na citrate- phosphate	5.0	36
14	B-II	α -fuc'ase b.k.	2	C7S _b	traces	Na citrate- phosphate	5.0	36
15	B-I	α -fuc'ase c.l.	0.25	ϕ	0	Na citrate	4.0	36
16	B-II	α -fuc'ase c.l.	0.25	ϕ	0	Na citrate	4.0	36
17	Tetra _b -I	β -gal'ase + β -h'ase j.b.	0.4 + 0.4	LcOse ₂ Cer (Cerebroside)	80 (10)	Na citrate	4.5	36
18	Hexa _b -II	β -gal'ase + β -h'ase j.b.	0.4 + 0.4	LcOse ₂ Cer (Cerebroside)	80 (10)	Na citrate	4.5	36
19	H _b -I	α -fuc'ase c.l.	0.25	Tetra _b -I	60	Na citrate	4.0	18 *
20	H _b -II	α -fuc'ase c.l.	0.25	Hexa _b -II	80	Na citrate	4.0	18 *

* Incubation without apo HDL in presence of Na taurocholate [taurocholate-glycolipid ratio 1 : 1 (w/w)].

presence of jack bean β -galactosidase and β -hexosaminidase. Within 18 hours of incubation, only negligible amounts of ceramide monosaccharide were formed. Control experiments proved, that the degradation of glycosphingolipids was largely dependent on the presence of apolipoprotein-glycolipid complexes (Fig. 1, lane b), whereas in the incubation mixture only trace amounts of reaction products were formed in the absence of apoproteins (Fig. 1, lane a).

B-I and B-II, reassembled with apo HDL and incubated with coffee bean α -galactosidase, quantitatively yielded H blood-group active ceramide pentasaccharide H_b-I and ceramide heptasaccharide H_b-II, respectively. Appreciable degradation of H_b-I and H_b-II by α -fucosidases from different sources to the corresponding ceramide tetrasaccharide Tetra_b-I or ceramide hexasaccharide Hexa_b-II, however, was

only observed in the presence of sodium taurocholate as detergent. Alternatively, Tetra_b-I and Hexa_b-II were also obtained from H_b-I and H_b-II by partial hydrolysis with 0.1 N trichloroacetic acid. Further degradation studies of B-I and B-II were exclusively performed with glycosphingolipid-apolipoprotein complexes. Fig. 2 demonstrates degradation of Tetra_b-I (lane b) and Hexa_b-II (lane c) down to glucocerebroside with ceramide dihexoside being the most abundant reaction product. The formation of glucocerebroside was found to be dependent on prolonged incubation periods (36 hours). Galactocerebroside could not be detected as reaction product. The incubation was performed with a mixture of β -galactosidase and β -N-acetyl-hexosaminidase from jack bean, thus permitting the consequence, that all saccharide linkages of Tetra_b-I and Hexa_b-II are of β -glycosidic nature.




Fig. 1. Enzymatic degradation of nLcOse₄Cer_{Tab} with a mixture of jack bean β -galactosidase and β -N-acetyl-hexosaminidase (assay no. 8, Table I). Lane a: incubation mixture in the absence of apolipoproteins; lane b: incubation mixture in the presence of apolipoproteins. 1: cerebroside; 2: ceramide disaccharide; 3: ceramide trisaccharide; 4: ceramide tetrasaccharide. The remaining bands arise from anthrone negative contaminants of the enzyme source.




Fig. 2. Borate-silica gel-thin layer chromatography of Tetra_B-I and Hexa_B-II after 36 hours incubation with a mixture of jack bean β -galactosidase and β -N-acetyl-hexosaminidase (assay no. 17 and 18, Table I). Lane a: cerebroside mixture; lane b: Tetra_B-I after incubation; lane c: Hexa_B-II after incubation; lane d: ceramide disaccharide from human erythrocytes. 1: glucosyl ceramide; 2: galactosyl ceramide; 3: anthrone negative contaminant of enzyme source; 4: ceramide disaccharide; 5: ceramide trisaccharide.

The results obtained from composition analysis^{22, 23}, linkage analysis by combined gas chromatography-mass spectrometry of partially methylated alditol acetates²³, sequence analysis of permethylated glycolipids²⁴ and from the enzymatic evaluation

of the anomeric configuration, presented in this paper, allow to deduce the following structures, for B-I:

α -D-galactopyranosyl-(1 \rightarrow 3)-[α -L-fucopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl-(1 \rightarrow 4)-N-acetyl- β -D-glucosaminosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl-(1 \rightarrow 1)-ceramide and for B-II:

α -D-galactopyranosyl-(1 \rightarrow 3)-[α -L-fucopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl-(1 \rightarrow 4)-N-acetyl- β -D-glucosaminosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 4)-N-acetyl- β -D-glucosaminosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl-(1 \rightarrow 1)-ceramide.

Sphingoside and C₂₄-fatty acid are the main components of the ceramide residues of both glycolipids^{23, 24}. The complete structures of these erythrocyte membrane antigens are demonstrated in Fig. 3. The results presented confirm the structure of B-I previously evaluated by Koscielak *et al.*²¹. The complete structure of B-II is presented for the first time.

A further purpose of this paper is to illustrate the usefulness of glycosphingolipid-lipoprotein complexes in enzymatic analysis of the anomeric structure of the oligosaccharide moiety. Previously, in enzymatic analysis of glycosphingolipids, taurocholate, cholate and Triton X-100 have been used to solubilize the respective compounds^{15–17}. However, tedious search for the adequate detergent mixture is often inconvenient^{17, 20, 23, 30–32} and inhibition of enzymes may occur. It is suggested that hydrophobic interaction between the ceramide moiety and lipophilic surface sides of apolipoprotein^{33, 34} facilitates the solubility of glycosphingolipids without perturbation of enzymatic activity.

The usefulness of reconstituted glycosphingolipid-apolipoprotein complexes is further emphasized by the ease, rapid isolation and high yield of reaction products without detergents as contaminants. Complete analysis of complex (branched) glycosphingolipids requires stepwise degradation of reaction products, which, in general, are available in only minor amounts. Presence of detergents, however, diminishes purity and yield of the reaction products and impairs subsequent analytical procedures especially methylation studies.

Another important aspect is the application of recombined glycosphingolipid-apoproteins to the diagnosis of glycosphingolipid storage diseases.




Fig. 3. Structures of blood-group B active ceramide hexa- (B-I) and octa-saccharide (B-II) of human erythrocyte membranes. They are based on composition analysis^{22, 23}, linkage analysis determined by combined gaschromatography-mass spectrometry²³ and sequence analysis by direct inlet mass spectrometry²⁴; evaluation of anomeric configuration is presented in this paper.

Studies employing α -galactosidase (Fabry disease), β -galactosidase (GM₁-gangliosidosis) and β -N-acetyl-hexosaminidase (Tay-Sachs disease) in the degradation of apolipoprotein-glycosphingolipid substrates now are intended to perform in our laboratories.

We thank Prof. Lagrou and Dr. van Dessel, Laboratory of Biochemistry, University of Antwerpen, for their generous gifts of jack bean β -galactosidase and N-acetyl- β -hexosaminidase. We also thank Dr. Okuyama of Seikagaku Chemical Co., Tokyo, for his supply of α -fucosidase from *Charonia lampas*. The skillfull technical assistance of Mrs. Monika Schmidt is gratefully acknowledged.

- ¹ J. Koscielak, A. Gardas, H. Gorniak, T. Pacuska, and A. Piasek, *Progress in Transfusion and Transplantation* (P. J. Schmidt, ed.), pp. 149–166, American Association of Blood Banks, 1972.
- ² S.-I. Hakomori, *Biochim. Biophys. Acta* **417**, 55–89 [1975].
- ³ H. Björndal, C. G. Hellerqvist, B. Lindberg, and S. Svensson, *Angew. Chem.* **82**, 643–652 [1970].
- ⁴ W. Stoffel and P. Hanfland, *Hoppe-Seyler's Z. Physiol. Chem.* **354**, 21–31 [1973].
- ⁵ K. Stellner, H. Saito, and S.-I. Hakomori, *Arch. Biochem. Biophys.* **155**, 464–472 [1973].
- ⁶ K.-A. Karlsson, J. Pascher, W. Pimlott, and B. E. Samuelsson, *Biomed. Mass Spectrometry* **1**, 49–56 [1974].
- ⁷ R. W. Ledeen, S. K. Kundu, H. C. Price, and J. W. Fong, *Chem. Phys. Lipids* **13**, 429–446 [1974].
- ⁸ P. Hanfland and H. Egge, *Chem. Phys. Lipids* **16**, 201–214 [1976].
- ⁹ Y.-T. Li and S.-C. Li, *Methods Enzymol.* **28**, 702–713 [1972].
- ¹⁰ O. P. Bahl and K. M. L. Agrawal, *Methods Enzymol.* **28**, 728–734 [1972].
- ¹¹ S. Gatt and M. M. Rapport, *Biochim. Biophys. Acta* **113**, 567–576 [1966].
- ¹² R. O. Brady, A. E. Gal, R. M. Bradley, and E. Martensson, *J. Biol. Chem.* **242**, 1021–1026 [1967].
- ¹³ C. A. Mapes, R. L. Anderson, and C. C. Sweeley, *FEBS Letters* **7**, 180–182 [1970].
- ¹⁴ K. Sandhoff, *FEBS Letters* **11**, 342–344 [1970].
- ¹⁵ S.-I. Hakomori, B. Siddiqui, Y.-T. Li, S.-C. Li, and C. G. Hellerqvist, *J. Biol. Chem.* **246**, 2271–2277 [1971].
- ¹⁶ C. A. Mapes and C. C. Sweeley, *Biochem. Biophys. Res. Commun.* **53**, 1317–1324 [1973].
- ¹⁷ A. Makita, J. Yokoyama, and W. Takahashi, *Hoppe-Seyler's Z. Physiol. Chem.* **354**, 1149–1152 [1973].
- ¹⁸ A. Slomiany, B. L. Slomiany, and M. I. Horowitz, *J. Biol. Chem.* **249**, 1125–1230 [1974].
- ¹⁹ J. F. Tallman, R. O. Brady, J. M. Quirk, M. Villaba, and A. E. Gal, *J. Biol. Chem.* **249**, 3489–3499 [1974].
- ²⁰ H. Tanaka, M. Meisler, and K. Suzuki, *Biochim. Biophys. Acta* **398**, 452–463 [1975].
- ²¹ J. Koscielak, A. Piasek, H. Gorniak, A. Gardas, and A. Gregor, *Eur. J. Biochem.* **37**, 214–225 [1973].
- ²² P. Hanfland and H. Egli, *Vox Sang.* **28**, 438–452 [1975].
- ²³ P. Hanfland, *Chem. Phys. Lipids* **15**, 105–124 [1975].
- ²⁴ P. Hanfland and H. Egge, *Chem. Phys. Lipids* **15**, 243–247 [1975].
- ²⁵ K. Stellner, K. Watanabe, and S.-I. Hakomori, *Biochemistry* **12**, 656–661 [1973].
- ²⁶ T. Eto, Y. Ichikawa, K. Nishimura, S. Ando, and T. Yamakawa, *J. Biochem. (Tokyo)* **64**, 205–213 [1968].
- ²⁷ S. E. Lux, K. M. John, and H. B. Brewer jr., *J. Biol. Chem.* **247**, 7510–7518 [1972].
- ²⁸ E. L. Kean, *J. Lipid Res.* **7**, 449–452 [1966].
- ²⁹ N. S. Radin, F. B. Lavin, and J. B. Brown, *J. Biol. Chem.* **217**, 789–796 [1955].
- ³⁰ M. W. Ho, *Biochem. J.* **133**, 1–10 [1973].
- ³¹ D. A. Wenger, M. Sattler, C. Clark, H. Tanaka, K. Suzuki, and G. Dawson, *Science* **188**, 1310–1312 [1975].
- ³² H. Tanaka and K. Suzuki, *J. Biol. Chem.* **250**, 2324–2332 [1975].
- ³³ G. Assmann and H. B. Brewer jr., *Proc. Nat. Acad. Sci. U.S.A.* **71**, 1534–1538 [1974].
- ³⁴ J. P. Segrest, R. L. Jackson, J. D. Morrisett, and A. M. Gotto jr., *FEBS Letters* **38**, 247–253 [1974].